PMID- 29249742
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20181202
IS  - 0387-821X (Print)
IS  - 0387-821X (Linking)
VI  - 39
IP  - 4
DP  - 2017
TI  - [Analysis of Advanced or Postoperative Recurrent Non-small Lung Cancer Cases 
      Treated with Nivolumab].
PG  - 291-297
LID - 10.7888/juoeh.39.291 [doi]
AB  - Recent developments in cancer immunotherapy are remarkable. Many reports have 
      described the clinical effects of immune checkpoint inhibitors (ICIs), supporting 
      their utility as a promising therapy that will achieve prominent effects even in 
      patients resistant to cytotoxic anticancer drugs or gene-targeting therapy. ICIs 
      may also prolong overall survival. We analyzed 10 cases of advanced lung cancer 
      targeted with nivolumab, which is one of ICIs in our hospital and reviewed the 
      literature regarding ICIs. We retrospectively analyzed 10 cases that consisted of 
      6 males and 4 females, which comprised 7 adenocarcinomas, 2 squamous cell 
      carcinomas and one pleomorphic carcinoma. Epidermal growth factor receptor (EGFR) 
      and anaplastic lymphoma kinase mutations were negative in all the adenocarcinoma 
      cases. The 10 analyzed cases included 9 inoperable cases and 1 postoperative 
      recurrent case, 8 second-line cases, a third-line case, and a fourth-line case. 
      The average frequency of administrations of nivolumab was 7.4 times. The survival 
      rate was calculated by using the Kaplan-Meier method. The clinical responses to 
      nivolumab were partial response in 2 cases, stable disease in 4 cases, and 
      progressive disease in 4 cases. In the 10 cases, the response rate and disease 
      control rate were 20% and 60%, respectively. The median progression-free survival 
      time and median survival time were 115 days and 126 days, respectively. We 
      observed 2 cases of dermatitis and one each of pyrexia, general fatigue and 
      drug-induced pneumonia as adverse events (AEs). One of these AEs was severe 
      (Stevens-Johnson syndrome grade 4) but could be treated by steroid pulse therapy, 
      steroid ointment and instillation. Among the 10 examined cases of advanced lung 
      cancer treated with ICIs at our hospital, ICIs proved effective in 2 cases. 
      However, we also experienced a case with Stevens-Johnson syndrome grade 4 as a 
      severe AE. These findings suggest that while ICIs may be effective in treating 
      patients, candidates for ICIs must be carefully selected and cautiously observed.
FAU - Ichiki, Yoshinobu
AU  - Ichiki Y
AD  - Department of Chest Surgery, Onga Nakama Medical Association Onga Hospital, 
      Japan.
AD  - Second Department of Surgery, School of Medicine, University of Occupational and 
      Environmental Health, Japan.
FAU - Iwanami, Takashi
AU  - Iwanami T
AD  - Department of Chest Surgery, Onga Nakama Medical Association Onga Hospital, 
      Japan.
FAU - Kakizoe, Kesei
AU  - Kakizoe K
AD  - Department of Surgery, Onga Nakama Medical Association Onga Hospital, Japan.
FAU - Hamatsu, Takayuki
AU  - Hamatsu T
AD  - Department of Surgery, Onga Nakama Medical Association Onga Hospital, Japan.
FAU - Suehiro, Taketoshi
AU  - Suehiro T
AD  - Department of Emergency, Onga Nakama Medical Association Onga Hospital, Japan.
FAU - Yoneda, Kazue
AU  - Yoneda K
AD  - Second Department of Surgery, School of Medicine, University of Occupational and 
      Environmental Health, Japan.
FAU - Tanaka, Fumihiro
AU  - Tanaka F
AD  - Second Department of Surgery, School of Medicine, University of Occupational and 
      Environmental Health, Japan.
FAU - Sugimachi, Keizo
AU  - Sugimachi K
AD  - Department of Surgery, Onga Nakama Medical Association Onga Hospital, Japan.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - J UOEH
JT  - Journal of UOEH
JID - 7909645
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*drug therapy/surgery
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Nivolumab
MH  - Recurrence
MH  - Skin Diseases/chemically induced
OTO - NOTNLM
OT  - PD-1
OT  - immune checkpoint inhibitor
OT  - immune therapy
OT  - lung cancer
OT  - nivolumab
EDAT- 2017/12/19 06:00
MHDA- 2018/06/07 06:00
CRDT- 2017/12/19 06:00
PHST- 2017/12/19 06:00 [entrez]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
AID - 10.7888/juoeh.39.291 [doi]
PST - ppublish
SO  - J UOEH. 2017;39(4):291-297. doi: 10.7888/juoeh.39.291.